YISHENG PHARM(SZ:002566) Xin Lang Cai Jing·2025-10-31 05:57Core Insights - Yisheng Pharmaceutical, established in June 1997 and listed on the Shenzhen Stock Exchange in March 2011, is a well-known Chinese traditional medicine company with strong technical accumulation and market advantages in R&D, production, and sales of traditional Chinese medicine [1] Group 1: Financial Performance - In Q3 2025, Yisheng Pharmaceutical achieved a revenue of 476 million yuan, ranking 56th among 69 companies in the industry, with the industry leader Baiyunshan generating 61.606 billion yuan and the average revenue being 3.755 billion yuan [2] - The net profit for the same period was 24.4188 million yuan, placing the company 49th in the industry, while the top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan, with the industry average at 447 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Yisheng Pharmaceutical's debt-to-asset ratio was 22.08%, down from 22.92% year-on-year, which is lower than the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 75.11%, slightly up from 74.80% year-on-year, and significantly higher than the industry average of 52.44% [3] Group 3: Executive Compensation - The chairman, Zhang Yisheng, received a salary of 1.05 million yuan in 2024, unchanged from 2023, while the general manager, Xue Xiaomin, earned 716,000 yuan, a slight decrease from 717,400 yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.71% to 19,600, while the average number of circulating A-shares held per shareholder increased by 0.72% to 11,800 [5] - Among the top ten circulating shareholders, Nuoan Multi-Strategy Mixed A (320016) became the eighth largest shareholder with 1.9863 million shares [5]